Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factor-acetylhydrolase (PAF-AH) activity in non-obese women with PCOS

Gynecological Endocrinology

Volumn 28, Issue 11, 2012, Pages 874-878

  Bayrak, Tulin ^a   Dursun, Polat ^b   Bayrak, Ahmet ^c   Gültekin, Murat ^d   Kolusari, Ali ^e   Çakir, Erdinç ^f   Ozyurt, Merve ^b   Zeyneloglu, Hulusi B ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c ORDU UNIVERSITY   (Turkey)

^d MINISTRY OF HEALTH   (Turkey)

^e YUZUNCU YIL UNIVERSITY   (Turkey)

^f GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

ADMA; Atherosclerotic heart disease; Homocysteine thiolactonase; PAF AH; PCOS; PON1

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANDROSTENEDIONE; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; ESTRADIOL; FOLLITROPIN; GLUCONOLACTONASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; N(G),N(G) DIMETHYLARGININE; PARAOXONASE LACTONASE; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGE; AMINO ACID BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ESTROGEN BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; ARGININE; ARYLDIALKYLPHOSPHATASE; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; HUMANS; OBESITY; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 84867565479     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.683068     Document Type: Article

References (31)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011.
2. ACOG Practice Bulletin. Polycystic ovary syndrome. Number 41. Int J Gynecol Obstet 2003;80:335-348.
3. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: Initial results from a case-control study. Am J Obstet Gynecol 1996;174:1224-9; discussion 1229.
4. Dursun P, Demirtas E, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: An additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod 2006;21:104-108.
5. Fenkci IV, Serteser M, Fenkci S, Kose S. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med 2007;52:879-883.
6. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004;11:412-419.
7. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: Studies in PON1-knockout mice. Free Radic Biol Med 2003;34:774-784.
8. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000;275:3957-3962.
9. Beltowski J. Protein homocysteinylation: A new mechanism of atherogenesis? Postepy Hig Med Dosw (Online) 2005;59:392-404.
10. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008;93:82-90.
11. Barathi S, Angayarkanni N, Pasupathi A, Natarajan SK, Pukraj R, Dhupper M, Velpandian T, et al. Homocysteinethiolactone and paraoxonase: Novel markers of diabetic retinopathy. Diabetes Care 2010;33:2031-2037.
12. Fan P, Liu HW, Wang XS, Zhang F, Song Q, Li Q, Wu HM, Bai H. Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome. Hum Reprod 2010;25:1288-1294.
13. Rotterdam/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
14. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986;293:355-359.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
16. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000;28:1335-1342.
17. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
18. Chen BM, Xia LW, Zhao RQ. Determination of N(G),N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;692:467-471.
19. Stafforini DM, McIntyre TM, Prescott SM. Methods Enzymol. 1990;187: 344-357.
20. Wild RA. Polycystic ovary syndrome: A risk for coronary artery disease? Am J Obstet Gynecol 2002;186:35-43.
21. Dahlgren E, Janson PO, Johansson S, Lapidus L, Od A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604.
22. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991;86:193-199.
23. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:330-335.
24. Kosaka T, Yamaguchia M, Motomura T, Mizuno K. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clinica Chimica Acta. 2005;359:156-162.
25. Mohamadin AM, Habib FA, Elahi TF. Serum paraoxonase 1 activity and oxidant/antioxidant status in Saudi women with polycystic ovary syndrome. Pathophysiology 2010;17:189-196.
26. Tavori H, Aviram M, Khatib S, Musa R, Mannheim D, Karmeli R, Vaya J. Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 (PON1) activity via reaction with PON1 free sulfhydryl cysteine 284. Free Radic Biol Med 2011;50:148-156.
27. Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, Hatzistilianou M, et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2008;196:958-965.
28. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metab Clin Exp 2004;53:1574-1579.
29. Stlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420-1426.
30. Wan DH, Fan P, Bai H, Song Q, Liu HW. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance]. Zhonghua Fu Chan Ke Za Zhi 2010;45:30-34.
31. Li Y, Fan P, Bai H, Wan DH, Liu HW. [The activity of platelet activating factor acetylhydrolase and its metabolic profile in patients with polycystic ovary syndrome]. Sichuan Da Xue Xue Bao Yi Xue Ban 2009;40:1066-1070.